Product Description: AZ960 is a potent and specific inhibitor of the JAK2 kinase with a Ki of 0.45 nM.
Applications: Cancer-Kinase/protease
Formula: C18H16F2N6
References: [1]Ikezoe T, et al. Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia. Int J Cancer. 2011 Nov 15;129(10):2512-21./[2]Yang J, et al. AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells. Mol Cancer Ther. 2010 Dec;9(12):3386-95./[3]Valenciano AL, et al. Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor. Bioorg Med Chem. 2016 Oct 1;24(19):4647-51./[4]Gozgit JM, et al. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem. 2008 Nov 21;283(47):32334-43.
CAS Number: 905586-69-8
Molecular Weight: 354.36
Compound Purity: 97.08
Research Area: Cancer
Solubility: DMSO : ≥ 30 mg/mL
Target: Apoptosis;JAK;Parasite;Virus Protease
Deutsch
English
